Investors Say Chancery Wrong To OK $3.8B Ligand Note Fix
An attorney for traders fighting over a disputed formula for cashing in Ligand Pharmaceuticals Inc. notes told Delaware's Supreme Court on Wednesday that the Chancery Court disregarded multiple investor protections when...To view the full article, register now.
Already a subscriber? Click here to view full article